Chronic Spontaneous Urticaria (CSU) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

According to the literature survey, the prevalence of chronic spontaneous urticaria (CSU) was estimated to be 0.75% to 1.02?ses within adults, however, ~ 30% to 55% of patients are diagnosed and symptomatic. 10% to 15% of patients are being diagnosed with mild, 29% to 31% of patients are being diagnosed with moderate and 27% to 29% patients are being diagnosed with a severe type of CSU. An estimated 10% to 12% of adults have experienced at least 1 episode of CSU at some time in their lives.

Read more:- Chronic Spontaneous Urticaria (CSU) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Chronic-Spontaneous-Urticaria-CSU-forecast

Comprehensive insight on patient segmentation based on age, sex, disease conditions, Severity (Mild, Moderate & Severe), patient Characteristics, Signs & Symptoms, Clinical Manifestations, Treatment types has been provided in the epidemiology section of the Chronic Spontaneous Urticaria (CSU) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

KOL database for PMR

In terms of pharmacologic therapies, there are several drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies and Drug: Patients will be randomized to receive Benralizumab; AstraZeneca, SAR231893; Sanofi, CT-P39; Celltrion, Ligelizumab; Novartis Pharmaceuticals, CDX-0159; Celldex Therapeutics, LY3454738; Eli Lilly, UCB8600; UCB Biopharma, UB-221; United BioPharma, UB-221; UBP Greater China (Shanghai) Co., Ltd, GDC-0853; Genentech, Inc., KPL-716; Kiniksa Pharmaceuticals, Ltd.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
Dry Age-Related Macular Degeneration – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Tardive Dyskinesia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Homocystinuria – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Opioid-Induced Constipation (OIC) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Bronchiectasis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Chronic Spontaneous Urticaria (CSU) market forecast, Chronic Spontaneous Urticaria (CSU), Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU) market outlook report, Chronic Spontaneous Urticaria (CSU) competitive landscape